Study Of Ssr AAV8-Kallistatin On Liver Fibrosis Treatment

Liver fibrosis is an important part of the further development of all kinds of chronic liver disease and deterioration, if we can eliminate the pathogenic factors in liver fibrosis stage and give appropriate treatment, meaning a lot in our country. Fibrosis liver, which always accompanied with lacking of oxygen, inflammation, oxidative stress, symptoms of portal hypertension and vascular proliferation, which means effective anti-liver fibrosis drugs should be on all targets and through all ways. But most of these drugs are recombinant proteins, need repeated dose. At the same time, Clinical medicine shows that stable dosing is more effective and less side effects than intermittent peak dosing. And the emerging gene therapy technology provide the effective means to stable dosing.This reach is to compare the curative effect of ssr AAV2-Kal and ssr AAV8-Kal to liver fibrosis and their liver targeting property and stability in the body.This paper is based on Cl4 induced mice liver fibrosis model. We compare the liver fibrosis curative effect of the two gene drugs through the appearance of mice, tissue section, serum fibrosis index and some fibrosis related tissue indexes. Than, preliminary discussed the reason ssr AAV8-Kal is better performed on liver fibrosis treatment than ssr AAV8-Kal through serum kallistatin expression level and tissue distribution.The research shows that in the same dosage and dosing method, the curative effective of ssr AAV8-Kal on liver fibrosis is more obvious than ssr AAV2-Kal, many indicators tend to return to normal levels. The main reason is ssr AAV8 might escape the nature immune antibody clearance in the body and express more efficiently than ssr AAV2.This research not only confirmed the effectiveness, convenience and high efficiency of ssr AAV8-Kallistatin in the treatment of liver fibrosis, convenience and high efficiency, but also provide important basis for ssr AAV8-Kal clinical research.